Shares


Creating value with biosimilars

Through our biosimilar development projects, Formycon creates not only highly effective, more affordable biologic drugs for patients but also long-term value for its investors. Biosimilars are a new class of medicines with a very promising future, and our product candidates are targeted at multi-billion-dollar markets.


Formycon AG share chart


Shareholder structure

15% institutional investors
35% family offices
15% founders and management
35% free float


Legal form

German stock corporation (Aktiengesellschaft)

Initial exchange listing

December 20, 2010


ISIN

DE000A1EWVY8

WKN

A1EWVY


Exchange and market segment

Frankfurt Stock Exchange “Scale” Segment (Open Market)

Share type

Bearer shares without par value


Registered capital

EUR 9,422,603.00

Shares outstanding

9,422,603 bearer shares


Capital Market Partner

Wolfgang Steubing AG

Designated Sponsors

Wolfgang Steubing AG
Hauck & Aufhäuser Privatbankiers KGaA